The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro

British Journal of Cancer

Volumn 95, Issue 8, 2006, Pages 1020-1027

  Alain, T ^a   Kim, M ^a   Johnston, R N ^a   Urbanski, S ^a   Kossakowska, A E ^a   Forsyth, P A ^a   Lee, P W K ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cured cells; Persistent infection; Reovirus oncolysis; Tumour regression

Indexed keywords

N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURKITT LYMPHOMA; CANCER REGRESSION; CARCINOGENESIS; CELL ISOLATION; CELL KILLING; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAJI CELL; REOVIRUS; SCID MOUSE; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT;

ANIMALS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; HUMANS; LEUCINE; MAMMALIAN ORTHOREOVIRUS 3; MICE; MICE, SCID; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TIME FACTORS; VIRION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33750214693     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603363     Document Type: Article

References (42)

1. Ahmed R, Fields BN (1982) Role of the S4 gene in the establishment of persistent reovirus infection in L cells. Cell 28: 605-612
2. Ahmed R, Canning WM, Kauffman RS, Sharpe AH, Hallum JV, Fields BN (1981) Role of the host cell in persistent viral infection: coevolution of L cells and reovirus during persistent infection. Cell 25: 325-332
3. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PW, Kossakowska AE (2002) Reovirus therapy of lymphoid malignancies. Blood 100: 4146-4153
4. Amerongen HM, Wilson GA, Fields BN, Neutra MR (1994) Proteolytic processing of reovirus is required for adherence to intestinal M cells. J Virol 68: 8428-8432
5. Baer GS, Dermody TS (1997) Mutations in reovirus outer-capsid protein sigma3 selected during persistent infections of L cells confer resistance to protease inhibitor E64. J Virol 71: 4921-4928
6. Baer GS, Ebert DH, Chung CJ, Erickson AH, Dermody TS (1999) Mutant cells selected during persistent reovirus infection do not express mature cathepsin L and do not support reovirus disassembly. J Virol 73: 9532-9543
7. Bass DM, Bodkin D, Dambrauskas R, Trier JS, Fields BN, Wolf JL (1990) Intraluminal proteolytic activation plays an important role in replication of type 1 reovirus in the intestines of neonatal mice. J Virol 64: 1830-1833
8. Bell JC, Lichty B, Stojdl D (2003) Getting oncolytic virus therapies off the ground. Cancer Cell 4: 7-11
9. Borsa J, Morash BD, Sargent MD, Copps TP, Lievaart PA, Szekely JG (1979) Two modes of entry of reovirus particles into L cells. J Gen Virol 45: 161-170
10. Chambers AF, Colella R, Denhardt DT, Wilson SM (1992) Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinogen 5: 238-245
11. Chandran K, Nibert ML (1998) Protease cleavage of reovirus capsid protein mu1/mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle. J Virol 72: 467-475
12. Chandran K, Farsetta DL, Nibert ML (2002) Strategy for nonenveloped virus entry: a hydrophobic conformer of the reovirus membrane penetration protein micro 1 mediates membrane disruption. J Virol 76: 9920- 9933
13. Chappell JD, Barton ES, Smith TH, Baer GS, Duong DT, Nibert ML, Dermody TS (1998) Cleavage susceptibility of reovirus attachment protein sigma1 during proteolytic disassembly of virions is determined by a sequence polymorphism in the sigma1 neck. J Virol 72: 8205- 8213
14. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334
15. Danis C, Mabrouk T, Garzon S, Lemay G (1993) Establishment of persistent reovirus infection in SC1 cells: absence of protein synthesis inhibition and increased level of double-stranded RNA-activated protein kinase. Virus Res 27: 253-265
16. Dermody TS (1998) Molecular mechanisms of persistent infection by reovirus. Curr Top Microbiol Immunol 233: 1-22
17. Dermody TS, Chappell JD, Hofler JG, Kramp W, Tyler KL (1995) Eradication of persistent reovirus infection from a B-cell hybridoma. Virology 212: 272-276
18. Dermody TS, Nibert ML, Wetzel JD, Tong X, Fields BN (1993) Cells and viruses with mutations affecting viral entry are selected during persistent infections of L cells with mammalian reoviruses. J Virol 67: 2055-2063
19. Ebert DH, Kopecky-Bromberg SA, Dermody TS (2004) Cathepsin B is inhibited in mutant cells selected during persistent reovirus infection. J Biol Chem 279: 3837-3851
20. Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A, Kitano S (2003) Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 9: 1218-1223
21. Flomenberg P, Piaskowski V, Harb J, Segura A, Casper JT (1996) Spontaneous, persistent infection of a B-cell lymphoma with adenovirus. J Med Virol 48: 267-272
22. Golden JW, Linke J, Schmechel S, Thoemke K, Schiff LA (2002) Addition of exogenous protease facilitates reovirus infection in many restrictive cells. J Virol 76: 7430-7443
23. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62: 1696-1701
24. Kao YS, Sundin DR, Gebhardt BM (1999) Persistent infection of a lymphoma cell line by herpes simplex virus. Am J Hematol 62: 93-98
25. Kilani RT, Tamimi Y, Hanel EG, Wong KK, Karmali S, Lee PW, Moore RB (2003) Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Res 93: 1-12
26. Kirn D (2002) Virotherapy for cancer: current status, hurdles, and future directions. Cancer Gene Ther 9: 959-960
27. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
28. Lee PW, Hayes EC, Joklik WK (1981) Characterization of anti-reovirus immunoglobulins secreted by cloned hybridoma cell lines. Virology 108: 134-146
29. Minato N, Bloom BR, Jones C, Holland J, Reid LM (1979) Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice. J Exp Med 149: 1117-1133
30. Morris DG, Forsyth PA, Paterson AH, Fonseca K, Difrancesco LM, Thompson BG, Coffey MC (2002) A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. ASCO Annual Meeting. Orlando, FL, USA
31. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW (2002) Reovirus oncolysis of human breast cancer. Hum Gene Ther 13: 641-652
32. Rubin H (2003) Microenvironmental regulation of the initiated cell. Adv Cancer Res 90: 1-62
33. Schattner A, Rager-Zisman B, Bloom BR (1985) Persistent viral infection affects tumorigenicity of a neuroblastoma cell line. Cell Immunol 90: 103-114
34. Sebti SM, Jani JP, Mistry JS, Gorelik E, Lazo JS (1991) Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Res 51: 227-232
35. Smith RE, Zweerink HJ, Joklik WK (1969) Polypeptide components of virions, top component and cores of reovirus type 3. Virology 39: 791-810
36. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J 17: 3351-3362
37. Taber R, Alexander V, Whitford W (1976) Persistent reovirus infection of CHO cells resulting in virus resistance. J Virol 17: 513-524
38. Tyler KL, Fields BN (1996) Reoviruses. In Fields Virology Fields BN, Knipe DM, Howley PM (eds) Philadelphia, PA: Lippincott-Raven, pp 1597-1623
39. Verdin EM, Maratos-Flier E, Carpentier JL, Kahn CR (1986) Persistent infection with a nontransforming RNA virus leads to impaired growth factor receptors and response. J Cell Physiol 128: 457-465
40. Wetzel JD, Wilson GJ, Baer GS, Dunnigan LR, Wright JP, Tang DS, Dermody TS (1997) Reovirus variants selected during persistent infections of L cells contain mutations in the viral S1 and S4 genes and are altered in viral disassembly. J Virol 71: 1362-1369
41. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903-912
42. Wolfson M, Gopas J, Katorza A, Udem SA, Segal S, Rager-Zisman B (1991) Regulatory effects of persistent measles virus infection on tumorigenicity and protooncogene expression in neuroblastoma cells. Cancer Detect Prev 15: 171-176